← Eichor
Study identifier: NCT07365267 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study on the Cosmetic Outcome and Safety Evaluation of 3D Printed Biodegradable Biological Mesh for One-Stage Breast Reconstruction After Radical Mastectomy

Condition: Breast Cancer · Breast Reconstruction After Mastectomy · 3D-Printed Biodegradable Biological Mesh  ·  Sponsor: Xijing Hospital

PhaseNA
Planned participants25
Who can joinFemale, 18 Years to 70 Years
Healthy volunteersNo

About this study

Primary objective of this trial: To evaluate the clinical performance (aesthetic outcome and quality of life) and safety of a 3D-printed biodegradable biological mesh in post-mastectomy immediate breast reconstruction. The study targets adult women undergoing total mastectomy for breast cancer followed by implant-based reconstruction. It aims to determine the utility of the 3D-printed biodegradable mesh in implant-based breast reconstruction, assess its influence on tissue regeneration, postoperative cosmetic result, and complication profile.

This description comes directly from the study's public registry record.

Talk to the study team

Ju Liang Zhang, Prof.  ·  029-84775271  ·  vascularzhang@163.com

Mei Ling Huang, MD  ·  029-84775271  ·  huangmeiling@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

the First Affiliated Hospital of the Air Force Medical UniversityXi'an, Shaanxi, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07365267